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Abstract
Background: Genetic polymorphisms in genes involved in pain modulation have been reported to be associated
to opioid efficacy and safety in different clinical settings.
Methods: The association between COMT Val158Met polymorphism (rs4680) and the inter-individual differences in
the response to opioid analgesic therapy was investigated in a cohort of 87 Italian paediatric patients receiving
opioids for cancer pain (STOP Pain study). Furthermore, a systematic review of the association between opioid
response in cancer patients and the COMT polymorphism was performed in accordance with the Cochrane
Handbook and the Prisma Statement.
Results: In the 87 paediatric patients, pain intensity (total time needed to reach the lowest possible level) was
significantly higher for G/G than A/G and A/A carriers (p-value = 0.042). In the 60 patients treated only with
morphine, the mean of total dose to reach the same pain intensity was significantly higher for G/G than A/G and
A/A carriers (p-value = 0.010). Systematic review identified five studies on adults, reporting that opioid dose (mg
after 24 h of treatment from the first pain measurement) was higher for G/G compared to A/G and A/A carriers.
Conclusions: Present research suggests that the A allele in COMT polymorphism could be a marker of opioid
sensitivity in paediatric cancer patients (STOP Pain), as well as in adults (Systematic Review), indicating that the
polymorphism impact could be not age-dependent in the cancer pain context.
Trial registration: Registration number: CRD42017057831.
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Background
Opioid analgesics are the treatment of choice for
moderate-severe pain both in adults and in children [1,
2]. A significant variability both in efficacy and in safety
has been observed in many studies aimed at describing
inter-individual differences. In addition to demographic
and disease-related factors, much research has focused
on genetic variability [3]. Indeed, sequence variations in
genes involved in opioid pharmacokinetics and pharma-
codynamics, as well as in the modulation of pain path-
ways, have been reported to be associated with
parameters of efficacy, such as the dose or the time to
obtain analgesia, and of safety, such as the occurrence
and severity of opioid side effects, in different clinical
settings [3, 4]. Among genes associated with variability
in the response to opioid analgesics, the gene encoding
for catechol-o-methyltransferase (COMT) is known to
be involved in pain modulation, presumably through
dopamine-mediated change of enkephalins neuronal
content [5], followed in turn by a compensatory regula-
tion of μ-opioid receptors in various brain regions [5, 6].
In particular, the common (50% frequency in Cauca-
sian population) 472G > A single nucleotide polymorph-
ism (SNP) in exon 4 of the COMT gene, Val158Met
(rs4680), leading to a three- to four-fold reduced activity
of the enzyme [7, 8], has been shown to be associated to
higher sensory and regional density of μ-opioid receptors
and affect experimental pain ratings [9].
Malignancy- or chemotherapy-induced pain therapy is
a challenge for paediatric oncologists. Available informa-
tion on the impact of genetic variability in COMT on
the effect of opioids in cancer pain remains limited, es-
pecially in children [10]. In Europe, the incidence rate of
cancer in young subjects (0–14 years of age) is 13.9/
100,000 [1, 11], with leukemia and nervous system can-
cer being the most represented (incidence 4.7 and 2.4,
respectively). Between 3 and 5% of childhood cancers
are bone tumors with osteosarcoma representing the
most commonly diagnosed primary malignant cancer,
with an incidence rate of 4.0 and 3.1 in young male and
female subjects < 24 years, respectively [12].
While pharmacogenetic data on opioids in adult cancer
patients are limited, those in paediatric subjects are com-
pletely missing. Thus, the aim of Suitable Treatment for
Oncologic Pediatric Pain (STOP Pain) study was to investi-
gate the association between the most studied COMT poly-
morphism, rs4680, and the inter-individual differences in
response to opioid analgesic therapy in a cohort of paediat-
ric cancer patients receiving opioids. The opioid dose
employed and the modifications in pain intensity were eval-
uated as efficacy outcomes, and the number of central and
gastrointestinal adverse effects as safety outcomes.
Furthermore, to evaluate whether the impact of this
COMT polymorphism is age-dependent, data obtained
in paediatric patients were compared to existing data in
adult subjects. To this aim, a systematic review of pub-
lished studies was conducted separately for three differ-
ent outcomes: opioid dosing, pain intensity, and side
effects.
Methods
STOP Pain study
Materials and methods of the present study have been
already published in part by Lucenteforte et al. 2018
[13]. Briefly, STOP Pain is a prospective observational
cohort pilot study enrolling hospitalized patients (0–17
years) between June 2011 and December 2014. Being a
pilot study, we did not calculate the cohort sample size
to test our hypothesis and all recruitable patients were
enrolled. The study was approved by the institutional re-
view board of Meyer Children’s Hospital. A psychologist,
expert in paediatric pain management, administered to
children parents structured questionnaires including
demographic information, medical history, concomitant
illnesses, and children lifestyle. Data about treatment re-
sponsiveness were collected to take in account any con-
founding variable and/or effect modifier. Patients were
anonymized by unique Patient Code, and then matched
with genotyping results obtained using the Taqman assay
(ABI, Applied Biosystems, Foster City, CA).
Standard opioid conversion to intravenous (IV) mor-
phine equivalents (ME) was performed [13, 14]. The
dose of administered morphine was also considered sep-
arately by the other drugs. Regarding non-opioid analge-
sics, the conversion of these medications to IV ME was
not performed.
Three indicators of dose were used for pain relief
evaluation: cumulative dose (mg/kg) of IV ME adminis-
tered during the first 24 h of treatment or titration phase
(Dose24h); total dose (mg/kg) of IV ME from Day 1 to
the last day of pain therapy (Dosetot); mean dose (mg/
kg) required to achieve maximal total pain relief re-
ported by the patient (DoseVAS = 0). Pain relief evaluation
was also assessed using pain intensity scores. Children
pain was measured using three different scales: visual
analog scale (VAS) was compiled by 58 subjects over six
years of age; Wong & Baker FACES Pain Rating Scale
was administered to 5 children between the ages of four
and six years of age; Face, Legs, Activity, Cry and Con-
solability (FLACC) scale was used by nurses to assess
pain in 24 children (less than four years old) unable to
communicate their pain. These measures were per-
formed at time 0 (before treatment) and defined as PIto.
Then, two parameters for pain intensity were consid-
ered: difference between the pain intensity after 24
h-treatment and PIto (Δ VAS); time to reach the lowest
pain intensity reported by the patient (Time tot). The
number of side effects was analyzed using three
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categorical (presence/absence) variables: onset of any ad-
verse drug reactions (ADRs) and onset of gastrointes-
tinal or CNS effects. Each patient could experience more
than one ADR. ADRs were recorded every eight hours
for each patient.
Statistical analyses
Continuous variables were checked for normality by
using the Shapiro-Wilk W test. Differences of means for
normally distributed variables were compared by
one-way ANOVA; differences of medians for
non-normally distributed variables were compared by
Pearson chi-squared test. Differences of percentages of
categorical variables were compared by chi-square test.
We also evaluated association between efficacy (high
doses and high pain intensity, defined as values ≥me-
dians, versus low doses and low pain intensity, defined
as values <medians) and safety parameters (presence of
side effects versus no side effects) and COMT rs4680
polymorphism by calculating odds ratios (ORs) and 95%
confidence intervals (CIs) using logistic regression
models adjusted for gender, age, body mass index (BMI),
diagnosis, metastasis, pain location, and pain intensity at
baseline. We considered a p-value < 0.05 as significant.
The software STATA 14.2 (StataCorp, 2011; Stata Stat-
istical Software: Release 14. College Station, TX) was
used for all analyses.
Systematic literature review
Cochrane Handbook and the Prisma Statement for Sys-
tematic Reviews [15] were used to perform the present
review registered in PROSPERO with the number
CRD42017057831.
Studies were systematically searched in PUBMED and
EMBASE databases up to November 24, 2016 [13]. Full
search strategy was reported in Additional file 1. Fur-
thermore, we conducted an additional research for
COMT gene to find all possible articles using as search
key: COMT[tiab] AND cancer[tiab] AND opioid*[tiab].
Independent investigators (AP and GC) selected arti-
cles reviewing titles and abstracts. Two other independ-
ent reviewers (EL and VM) resolved through discussion
and consensus any disagreements.
Then, AP and GC independently read the full texts
selecting the original articles when patients were cancer
patients, involved drugs were opioids, outcomes were re-
lated to opioid non-response and safety, and one or
more genes were studied.
Mean age and gender of the sample, study type and
size, location, year of publication, drugs used and genetic
information (name of gene, investigated polymorphism
and main results) were collected for each study. By study
design, only results reported in papers investigating
COMT gene as factor associated to therapy outcome
were taken into consideration. “Quality Assessment Tool
for Observational Cohort and Cross-Sectional Studies”
[16] was used to assess the quality of the included stud-
ies (see the criteria reported in Additional file 2).
Results
STOP Pain study
Patient population
One hundred thirty-three patients were evaluated from
June 2011 to December 2014. Forty-six children were
not included in the study for the following reasons: re-
fusals of consent (n = 8), end of life patients (n = 12),
early discharge (before to administer the questionnaires;
n = 18), hospitalization in sterile room (n = 8). Table 1
showed the distribution of the main characteristics of
the 87 Italian subjects included in the STOP Pain study.
Of them, 56% were males. Most were older than 3 years
of age and 43% older than 12. BMI was < 25th percentile
in 42%, and between 25th and 75th in 26%. Main cancer
diagnoses were leukemia or lymphoma (39%), followed
by sarcoma (21%) and osteosarcoma (20%). Cancer me-
tastases were present in 26% of the cases; pain in oral
cavity in 49%, and skeletal pain in 16%. To achieve pain
relief, patients were primarily treated with morphine
(69%). A total of five patients (6%) were treated at least
once with codeine-containing medication, in particular
with a fixed dose combination of codeine and paraceta-
mol. Of them, four patients were administered an oral
preparation (codeine 30mg + paracetamol 500 mg), and
only one patient a rectal preparation (codeine 5 mg +
paracetamol 200 mg).
Biological samples of eight patients were not available
for medical reasons, however main characteristics of
these patients were comparable with those of genotyped
patients (see Additional files 3 and 4).
Influence of COMT polymorphism on efficacy and safety
parameters
None of the above characteristics was different among
the three genotype groups (p-values ≥ 0.05). Genotype
frequencies agreed with the Hardy–Weinberg equilib-
rium (p-value = 0.45) and consistent with 1000 Genome
Project Data for European population (EUR) [17].
Table 2 shows mean and standard deviation values of
opiate and morphine dose, pain intensity, and distribu-
tion of side effects in the three genotype groups. The
mean of Timetot significantly differed across the three
groups (p-value = 0.042). In particular, the mean for AG
and AA groups was lower than GG (p-value = 0.0094
and 0.0026, respectively). No difference was observed for
all the other considered variables (p-values ≥ 0.05).
Table 3 shows the association of efficacy and safety pa-
rameters with COMT rs4680 polymorphism. After the
adjustment for gender, age, BMI, diagnosis, metastasis,
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pain location and pain intensity at baseline, we found a
statistically significant association for the efficacy param-
eters Dosetot and Timetot. In particular, A/G subjects
needed a lower total amount of drugs compared to G/G
individuals (adjusted OR 0.27, 95% CI 0.08–0.87), and
patients heterozygous or homozygous for the A allele
reached the lowest pain intensity faster compared to G/
G individuals (OR 0.18, 95% CI 0.05–0.63 and OR 0.11,
95% CI 0.02–0.56, respectively). No significance was
found for the association of safety parameters and
COMT genotype.
Systematic literature review
Study selection
Systematic literature search produced 350 records. After
an initial screening of titles and abstracts, 239 studies
were excluded for the following reasons: not relevant
(137); reviews (39); not human studies (36 studies); case
Table 1 Characteristics of the 87 Italian subjects included in the STOP Pain Project: overall and stratified for COMT rs4680
polymorphism
Overall G/Ga A/Ga A/Aa p-
valueb
N (%) N (%) N (%) N (%)
87 24 (30.38) 42 (53.16) 13 (16.46)
Gender
Male 49 (56.32) 15 (62.50) 22 (52.38) 7 (53.85) 0.721
Female 38 (43.68) 9 (37.50) 20 (47.62) 6 (46.15)
Age (months)
0–36 18 (20.69) 4 (16.67) 8 (19.05) 4 (30.77) 0.466
> 36–144 32 (36.78) 10 (41.67) 18 (42.86) 2 (15.38)
> 144 37 (42.53) 10 (41.67) 16 (38.10) 7 (53.85)
BMI (percentile)
< 25th 33 (42.31) 5 (25.00) 18 (46.15) 5 (38.46) 0.490
25th- < 75th 20 (25.64) 8 (40.00) 8 (20.51) 4 (30.77)
≥ 75th 25 (32.05) 7 (35.00) 13 (33.33) 4 (30.77)
missing 9
Diagnosis
Brain Tumour 6 (6.90) 2 (8.33) 2 (4.76) – 0.728
Leukaemia and Lymphoma 34 (39.08) 11 (45.83) 18 (42.86) 4 (30.77)
Neuroblastoma 6 (6.90) 1 (4.17) 3 (7.14) 2 (15.38)
Osteosarcoma 17 (19.54) 2 (8.33) 8 (19.05) 3 (23.08)
Sarcoma 18 (20.69) 7 (29.17) 8 (19.05) 2 (15.38)
Others 6 (6.90) 1 (4.17) 3 (7.14) 2 (15.38)
Metastasis
No 64 (73.56) 19 (79.17) 26 (61.90) 12 (92.31) 0.067
Yes 23 (26.44) 5 (20.83) 16 (38.10) 1 (7.69)
Pain location
Abdominal 12 (13.79) 5 (20.83) 4 (9.52) 2 (15.38) 0.808
Oral cavity 43 (49.43) 11 (45.83) 23 (54.76) 6 (46.15)
Skeletal – Muscle 14 (16.09) 3 (12.50) 5 (11.90) 3 (23.08)
Other 18 (20.69) 5 (20.83) 10 (23.81) 2 (15.38)
Pain Intensity (PIto), mean (95% CI) 4.34 (3.88–4.81) 4.08 (3.33–4.84) 4.57 (3.89–5.25) 4.38 (2.81–5.96) 0.674
a
Drug
morphine 60 (68.97) 16 (66.67) 32 (76.19) 8 (61.54)
tramadol 19 (21.84) 5 (20.83) 9 (21.43) 3 (23.08) 0.632
oxycodone 2 (2.30) 1 (4.17) – –
codeine 2 (2.30) 1 (4.17) – 1 (7.69)
more than one 4 (4.60) 1 (4.17) 1 (2.38) 1 (7.69)
a Biological samples of 8 patients were not available for medical reasons. Genetic data were not available for technical reasons (failure of the genetic test)
b p-value from ANOVA
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Table 2 Efficacy and safety parameters according to COMT rs4680 polymorphism in the 87 subjects included in the STOP Pain
Project
Overall G/G A/G A/A p-value
Opioids
Dose (mg/kg)
Dose24h
mean (95% CI) 0.38 (0.33–0.42) 0.41 (0.30–0.52) 0.39 (0.33–0.45) 0.36 (0.23–0.48)
median (interquartile range) 0.41 (0.19–0.50) 0.43 (0.16–0.57) 0.42 (0.24–0.49) 0.43 (0.19–0.46) 0.921*
Dosetot
mean (95% CI) 2.57 (2.17–2.96) 3.34 (2.45–4.23) 2.35 (1.83–2.87) 2.24 (1.11–3.37)
median (interquartile range) 2.18 (1.20–3.50) 3.25 (1.73–5.23) 2.02 (1.26–2.97) 2.18 (1.06–3.07) 0.119*
DoseVAS = 0
mean (95% CI) 0.41 (0.27–0.55) 0.59 (0.18–1.01) 0.35 (0.22–0.48) 0.39 (0.03–0.75)
median (interquartile range) 0.26 (0.10–0.49) 0.36 (0.07–0.74) 0.21 (0.11–0.47) 0.25 (0.10–0.41) 0.568*
Pain Intensity
Δ VAS, N (%)
≤ 2 46 (54.12) 15 (62.50) 20 (50.00) 6 (46.15) 0.533**
≥ 2 39 (45.88) 9 (37.50) 20 (50.00) 7 (53.85)
Time tot (hours)
mean (95% CI) 140.43 (126.81–154.05) 166.87 (143.42–190.33) 133.67 (111.87–155.46) 116.61 (87.64–145.59) 0.042***
median (interquartile range) 133.00 (99.00–192.00) 190.50 (139.25–199.00) 130.00 (96.00–185.50) 120.00 (76.00–144.00)
Side effects, N (%)a
Gastrointestinalb 23 (26.44) 8 (33.33) 9 (21.43) 3 (23.08) 0.553**
CNSc 10 (11.49) 2 (8.33) 4 (9.52) 2 (15.38) 0.780**
Totald 32 (36.78) 10 (41.67) 14 (33.33) 4 (30.77) 0.736**
Morphine
Dose (mg/kg)
Dose24h
mean (95% CI) 0.49 (0.45–0.53) 0.55 (0.44–0.66) 0.47 (0.41–0.52) 0.49 (0.38–0.60)
median (interquartile range) 0.46 (0.41–0.57) 0.50 (0.43–0.65) 0.46 (0.40–0.55) 0.46 (0.43–0.60) 0.170*
Dosetot
mean (95% CI) 3.19 (2.72–3.67) 4.39 (3.49–5.30) 2.75 (2.14–3.35) 3.04 (1.48–4.60)
median (interquartile range) 2.93 (1.82–4.42) 4.52 (3.25) 2.23 (1.72–3.40) 2.98 (1.70–3.33) 0.050*
DoseVAS = 0
mean (95% CI) 0.54 (0.35–0.74) 0.88 (0.28–1.49) 0.41 (0.25–0.56) 0.56 (0.00–1.16)
median (interquartile range) 0.36 (0.17–0.60) 0.54 (0.36–0.96) 0.26 (0.14–0.52) 0.37 (0.20–0.48) 0.257*
Pain Intensity
Δ VAS, N (%)
≤ 2 29 (49.15) 10 (62.50) 16 (51.61) 2 (25.00) 0.221**
≥ 2 30 (50.85) 6 (37.50) 15 (48.39) 6 (75.00)
Time tot (hours)
mean (95% CI) 147.96 (131.56–164.36) 174.62 (149.82–199.43) 139.53 (113.56–165.50) 134.00 (96.72–171.28) 0.154***
median (interquartile range) 142.50 (101.50–193.50) 190.50 (150.00–199.00) 130.25 (100.5–188.75) 123.50 (99.50–173.25)
Side effects, N (%)a
Gastrointestinalb 14 (23.33) 5 (31.25) 6 (18.75) 2 (25.00) 0.621**
CNSc 6 (10.00) 1 (6.25) 2 (6.25) 1 (12.50) 0.817**
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Table 2 Efficacy and safety parameters according to COMT rs4680 polymorphism in the 87 subjects included in the STOP Pain
Project (Continued)
Overall G/G A/G A/A p-value
Totald 19 (31.67) 6 (37.57) 9 (28.13) 2 (25.00) 0.752**
Opioids: morphine equivalents (patients that used more than one opioid)
Morphine: patients that used only morphine
Dose24h: total dose (mg/kg) of intravenous (IV) morphine equivalents (ME) administered during the titration phase; Dosetot: total dose (mg/kg) of IV ME; DoseVAS =
0: mean dose (mg/kg) required to achieve total pain relief
PIto: pain intensity before treatment, measured with FLACC (Face, Legs, Activity, Cry, Consolability) or VAS (Visual Analogic Scale) numeric scale or WONG & BAKER
Pain Rating Scale (range: 0–10); Δ VAS: difference between the pain intensity after 24 h of treatment and PIto; Time tot: time in hours to reach the lowest pain
intensity possible
a N, number of patients who experienced that ADR; each patient could have experienced more than one ADRs
b Gastrointestinal effects included nausea/vomiting, diarrhea, and constipation
c CNS: Central Nervous System effects included agitation, drowsiness, headache, and sedation
d Total number of patients with gastrointestinal and/or central nervous system effects, and/or itching
* p-value from Pearson chi-squared test of the equality of the medians
** p-value form ANOVA
*** p-value from chi-squared test
Table 3 Association of efficacy and safety parameters with COMT rs4680 polymorphism in the 87 subjects included in the STOP
Pain Project
N (%)
ORa (95% CI)
G/G A/G A/A
Dose (mg/kg)
High Dose24h (≥0.41 vs < 0.41) 12 (50.00) vs 12 (50.00) 21 (52.50) vs 19 (47.50) 7 (53.85) vs 6 (46.15)
1 (reference) 0.66 (0.19–2.25) 0.80 (0.16–4.01)
High Dosetot (≥2.18 vs < 2.18) 16 (66.67) vs 8 (33.33) 18 (42.86) vs 24 (57.14) 7 (53.85) vs 6 (46.15)
1 (reference) 0.27 (0.08–0.87) 0.42 (0.09–1.98)
High DoseVAS = 0 (≥0.26 vs < 0.26) 14 (58.33) vs 10 (41.67) 26 (65.00) vs 14 (35.00) 9 (69.23) vs 4 (30.77)
1 (reference) 0.98 (0.30–3.24) 1.47 (0.29–7.40)
Pain Intensity
High ΔVAS (≥2 vs < 2) 14 (58.33) vs 10 (41.67) 20 (47.62) vs 22 (52.38) 6 (46.15) vs 7 (53.85)
1 (reference) 0.51 (0.15–1.65) 0.57 (0.12–2.82)
High Timetot (≥133 vs < 133) 19 (79.17) vs 5 (20.83) 19 (45.24) vs 23 (54.76) 4 (30.77) vs 9 (69.23)
1 (reference) 0.18 (0.05–0.63) 0.11 (0.02–0.56)
Side effects, N (%)
Gastrointestinalb 8 (33.33) vs 16 (66.67) 9 (21.43) vs 33 (78.57) 3 (23.08) vs 10 (76.92)
1 (reference) 0.56 (0.16–1.91) 0.46 (0.09–2.44)
CNSc 2 (8.33) vs 22 (91.67) 4 (9.52) vs 38 (90.48) 2 (15.38) vs 11 (84.62)
1 (reference) 1.39 (0.21–9.44) 1.62 (0.17–15.78)
Totald 10 (58.33) vs 10 (41.67) 14 (33.33) vs 28 (66.67) 4 (30.77) vs 9 (69.23)
1 (reference) 0.86 (0.29–2.56) 0.58 (0.13–2.54)
Dose24h: total dose (mg/kg) of intravenous (IV) morphine equivalents (ME) administered during the titration phase; Dosetot: total dose (mg/kg) of IV ME; DoseVAS =
0: mean dose (mg/kg) required to achieve total pain relief
PIto: pain intensity before treatment, measured with FLACC (Face, Legs, Activity, Cry, Consolability) or VAS (Visual Analogic Scale) numeric scale or WONG & BAKER
Pain Rating Scale (range: 0–10); Δ VAS: difference between the pain intensity after 24 h of treatment and PIto; Time tot: time in hours to reach the lowest pain
intensity possible
aOR and corresponding 95% confidence intervals from logistic regression models adjusted for gender, age, BMI, diagnosis, metastasis, pain location and pain
intensity at baseline
bGastrointestinal side effects comprehend nausea, vomiting, diarrhea and constipation
cCNS, Central Nervous System side effects comprehend agitation, drowsiness, headache and sedation
dTotal side effects comprehend the occurrence of gastrointestinal and CNS side effects, and itching
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reports (17); full text not available (10). We obtained the
full text of 45 articles. Of them, 11 studies were defined
not relevant because they did not focus on genotype ef-
fects on our clinical outcomes (pain relief and adverse
events), and four focused on cancer patients’ postopera-
tive pain and postoperative adverse events, thus they
were excluded. Characteristics of studies excluded after
full-text reading are shown in Additional file 5. Finally,
we included a total of 31 studies (see the flowchart of
study selection in Fig. 1): 30 from the above 45 studies
and 1 additional study obtained with further search
strategy (identifying 16 records).
Study quality assessment
Of the 31 selected papers, nine investigated COMT and
were analyzed in the present review [18–26]; none of the
studies was conducted on paediatric subjects. Assess-
ment of methodological quality was performed for the
considered studies using the Quality Assessment Tool
for Observational Cohort and Cross-Sectional Studies
[16]. All studies met the quality criteria regarding the re-
search question or objective (items 1), inclusion/
exclusion criteria and participants’ recruitment (item 4),
exposure of interest measurement prior to the outcome
measurement (item 6), length of follow-up (item 7), in-
dependent and dependent variable description/definition
(item 9 and 11), multiple assessment of the exposure
(item 10), and lost at follow-up (item 13). Only 28 and
33% of studies received negative responses for the items
2 and 14, respectively. Participation rate of eligible pa-
tients (items 3) and sample size justification (item 5)
were clearly described in 42 and 8% of studies, respect-
ively. Categories of exposure (item 8) and blinding of as-
sessors (item 12) were applicable only in 22 and 3% of
studies, respectively.
Study description
Table 4 shows the characteristics of five studies (re-
ported in nine papers) included in the systematic review.
Three studies were conducted in Europe, one in Japan,
and one in Tunisia. The EPOS study included the high-
est number of patients; drugs used were morphine in
three studies, morphine, methadone, fentanyl, hydro-
morphone, buprenorphine, ketobemidone, and
Fig. 1 PRISMA Flow diagram of the selection of studies searched with PUMBED and EMBASE and included in the systematic review
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Table 4 Characteristics of five studies (nine papers) investigating the association between COMT gene and opioid response and/or
side effects included in the systematic review
Study
name, [ref]
Study design Patients characteristics Opioid administered Data M/F Mean Age
(years)Opioid
dose
Pain Side
effects
EPOS study European
observational
study
Cancer pain patients Morphine, methadone, fentanyl,
hydromprphone, buprenorphine,
ketobemidone, oxycodone
[18]
(Klepstad,
2011)
2201 Caucasians X 1154/
1047
62.4
[19]
(Barratt,
2014)a
667 subjects treated with
transdermal fentanyl
334/
342
Median: 64
[20]
(Barratt,
2015)b
468 Caucasian subjects treated
with transdermal fentanyl
X X 218/
250
Median: 64
[21]
(Laugsand,
2011)
1579 subjects not receiving
chemotherapy and with
information on nausea and
vomiting
X 850/
729
61.9
[22]
Matsuoka,
2012
Japanese
observational
study
48 Opioid-treatment-naïve cancer
patients
Morphine X 25/23 69.0
[23, 24]
Rakvåg,
2005–2008
Norwegian
observational
study
207 Cancer pain Caucasian
patients
Morphine X X X 117/
90
63.2
[28] Ross,
2008
United
Kingdom
case-control
study
228 Cancer pain patients Morphine, Oxycodone, fentanyl,
methadone
X X 106/
122
57.2
[26] Chatti,
2016
Tunisian
observational
study
129 Cancer pain patients Morphine X 63/66 Number of
patients for
each age
group:
17-25 yrs.: 12
26-45 yrs.: 50
46-65 yrs.: 67
aBarratt, 2014 [19] was a subgroup analysis of Klepstad, 2011 [18] (i.e. 676 subjects treated with transdermal fentanyl)
bBarratt, 2015 [20] was a subgroup analysis of Barratt, 2014 [19] (i.e. 468 Caucasian subjects treated only with transdermal fentanyl)
Table 5 Association between opioid dose and COMT rs4680 polymorphism in the studies included in the systematic review
Study name [ref] Variable Genotype frequency
(N, %)
Results (type of measure) p-value
EPOS study [18] (Klepstad, 2011) Dose in mg after 24 h G/G (324, 22.18)
A/G (726, 49.69)
A/A (411, 28.13)
180 mg
180mg
160mg (median)
0.545
[22] Matsuoka, 2012 Dose in mg after 24 h G/G (19, 46.34)
A/G (18, 43.90)
A/A (4, 9.76)
43.7 ± 21.4
28.9 ± 3.2
30.0 ± 0.0 (mean ± SD)
0.03
[23] Rakvåg, 2005 Dose in mg after 24 h G/G (44, 21.25)
A/G (96, 46.38)
A/A (67, 32.37)
155 ± 160
117 ± 100
95 ± 99 (mean ± SD)
0.025
[26] Chatti, 2016 Total dose requirement
(continuous) AvsG
G/G (30, 23.3)
A/G (57, 44.2)
A/A (42, 32.6)
−2.10 (difference) 0.334
Need of escalation
(yes/no) AvsG
OR 0.76 (0.45; 1.27) 0.293
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oxycodone in another and morphine, oxycodone, fen-
tanyl, and methadone in the last study. Three studies re-
ported data on opioid dose as well as on pain and side
effects.
Tables 5, 6 and 7 report the evaluated association be-
tween opioid dose, pain intensity, and side effects with
COMT rs4680 polymorphism. Two studies included in
the systematic review agreed on the finding that opioid
Dose24h was lower among subjects with the A (158 Met)
allele [22, 23]. Only one study [26] reported an associ-
ation between the Dosetot of oral morphine and dose es-
calation, without reaching statistical significance.
Otherwise, no clear associations emerged with pain in-
tensity (measured with Brief Pain Inventory) or with side
effects, with the exception of the EPOS study in which
the intensity of nausea and vomiting (EORTC score) was
significantly lower among the subjects with A/G geno-
type (p-value = 0.002).
Prisma checklist validation is reported in
Additional file 6.
Comparison of STOP PAIN and systematic review results
Figure 2 allows a direct visualization via a forest plot of
the comparison of the STOP PAIN data with those in-
cluded in the systematic review, relative to the 24 h opi-
oid cumulative dose (when reported as mean ± standard
deviation (SD)).
Discussion
This is the first paediatric study addressing the role of
COMT polymorphism rs4680 in opioid treatment of
cancer patients as well as the inter-individual differences
in the response to opioid analgesic therapy. Further-
more, we also compared the obtained evidences to exist-
ing data in adults retrieved by means of a systematic
review of medical literature. The main result of the
STOP Pain study was that paediatric cancer patients
with the GG genotype needed a longer time to reach the
lowest possible pain intensity compared with the
A-containing genotypes. However, this association can
be due to chance, given the many interaction tests car-
ried out. The systematic review regarding adult cancer
patients showed that the Dose24h was lower among sub-
jects presenting the A allele [22, 23, 27], and no clear as-
sociation was found between the polymorphism and
either pain intensity or side effects.
Focusing on investigations into the role of COMT
rs4680 polymorphism in cancer pain, the G/G genotype
was shown to require higher morphine daily doses as
compared to G/A and A/A ones [22, 23, 27]. This asso-
ciation was not confirmed in Caucasian adults by a large
multicenter European (11 countries) study [18] and an
investigation on Tunisian patients [26]. Genetic hetero-
geneity (and cosmopolitan areas) could contribute to
this contradictory finding compared to the others
homogenous populations [22, 23].
On the other hand, the first study showed an associ-
ation of this polymorphism with opioid-induced nausea
[21]. In another study, morphine central side effects
were shown to be associated with a different COMT
polymorphism [28]. The relevance of the selected candi-
date gene was due to the association between the
catechol-O-methyltransferase and chronic pain: COMT
affects dopamine concentration in the prefrontal cortex
of the human brain, influencing pain regulation at differ-
ent levels [29]. Several of the most frequent SNPs within
COMT have been investigated in relation to mRNA ex-
pression, protein levels and enzyme activity. Principally,
even if a more complex genetic basis could not be ex-
cluded, the nonsynonymous SNP rs4680 variation in-
duced decreased enzyme thermostability and activity
[29]. This lower activity of COMT enzyme, with a con-
sequent increase of dopamine bioavailability [4], was re-
ported to increase opioid receptor density and to
enhance opioid analgesia and adverse effects in several
types of cancer pain [18, 21–23].
COMT polymorphisms associated with lower COMT
activity have been studied in several painful conditions,
such as postoperative surgery, cancer pain, neuropathic
pain, and migraine or headache [30], not only in adult
subjects but also in paediatric populations [31–34]. In
osteoarthritis, the low-activity allele of COMT [158Met
or A] was associated with increased hip pain in patients
with damaged hip [35]. Low COMT activity has been
Table 6 Association between pain intensity and COMT rs4680 polymorphism in the studies included in the systematic review
Study name [ref] Variable Genotype frequency (N, %) Results (type of measure) p-value
EPOS study [20] (Barratt, 2015) Brief Pain Inventory G/G (109, 23.59)
A/G (243, 52.60)
A/A (110, 23.80)
Not reported
[23] Rakvåg, 2005 Brief Pain Inventory after 24 h G/G (44, 21.25)
A/G (96, 46.38)
A/A (67, 32.37)
3.9 ± 2.2
3.7 ± 2.6
3.5 ± 2.3
(mean ± SD)
> 0.05
[28] Ross, 2008 Brief Pain Inventory after 24 h G/G (46, 20.81)
A/G (119, 53.85)
A/A (56, 25.34)
Not reported 0.897
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related to increased pain sensitivity in experimental
tests, whereas high activity COMT haplotypes protect
from the development of chronic muscle-skeletal painful
conditions [36].
In our sample of paediatric patients, the association
with rs4680 COMT polymorphism was found using the
total dose requested for maximal possible pain reduc-
tion, whereas the 24-h dose that correlated in adult can-
cer patients only showed a slight tendency towards
association. The reasons for this discrepancy may reside
in differences between adults and children in both
pharmacokinetics and pharmacotherapy regimens. In
fact, while pharmacological therapy in adults is based on
fixed-dose increments, treatment in children needs to be
personalized based on age and weight (or body surface),
considering incomplete organ maturation, differences in
body composition and plasma proteins, in receptor
density and type. For example, children younger than 11
years show faster clearance of morphine and morphine
metabolites than older subjects [37]. Furthermore, there
is wide variability in morphine clearance among paediat-
ric subjects, particularly neonates and infants [38].
For these patients, analgesics are the drug class most
commonly used in hospital [39], with morphine being
one of the most used among the strong opioids [40], and
some of these drugs (i.e., oxycodone, tramadol) are gen-
erally used in an off-label manner, with a potential in-
creased risk of adverse effects. Moreover, experimental
and clinical data support the presence of significant dif-
ferences between opioid pharmacological characteristics
[41]. Although all opioids interact with the mu (μ) opi-
oid receptor as primary target, these compounds differ
in chemical structures, in pharmacokinetics, efficacy, ef-
fectiveness, and toxicity [42]. Moreover, the use of equia-
nalgesic tables raises several concerns: (1) calculating the
median equivalence values based on them may be in-
accurate, mainly for possible different variable equiva-
lence ranges within or between different equianalgesic
tables; (2) equivalence ratios derived from computation
rather than from clinical data could be devoid of clinical
Table 7 Association between side effects and COMT rs4680 polymorphism in the studies included in the systematic review
Study name [ref] Variable Genotype frequency (N,
%)
Results (type of
measure)
p-
value
EPOS study [20] (Barratt,
2015)
Tiredness, Depression, Cognitive Dysfunction,
Constipation
G/G (109, 23.59)
A/G (243, 52.60)
A/A (110, 23.80)
Not reported
[21] (Laugsand, 2011) Nausea and Vomiting EORTC Score G/G (341, 21.93)
A/G (787, 50.61)
A/A (427, 27.46)
25.8 ± 30.5
21.5 ± 26.6
26.2 ± 29.2
(mean ± SD)
0.002
[23] Rakvåg, 2005 Fatigue EORTC Score G/G (44, 21.25)
A/G (96, 46.38)
A/A (67, 32.37)
73 ± 23
62 ± 24
66 ± 22
(mean ± SD)
> 0.05
Nausea and vomiting EORTC Score 30 ± 27
24 ± 26
29 ± 27
(mean ± SD)
> 0.05
Dyspnea EORTC Score 39 ± 35
38 ± 34
32 ± 33
(mean ± SD)
> 0.05
Sleep EORTC Score 39 ± 35
38 ± 34
32 ± 33
(mean ± SD)
> 0.05
Appetite EORTC Score 64 ± 36
49 ± 38
53 ± 38
(mean ± SD)
> 0.05
Constipation EORTC Score 56 ± 41
57 ± 37
54 ± 37
(mean ± SD)
> 0.05
[28] Ross, 2008 Central side effect G/G (46, 20.81)
A/G (119, 53.85)
A/A (56, 25.34)
Not reported 0.956
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context and might be grossly inaccurate; (3) formula-
tions containing an opioid and other analgesics (i.e.,
nonsteroidal anti-inflammatory drugs) cannot be com-
pared to a single opioid and calculation of equivalents
may be difficult [43].
Overall, results obtained for adults and children in
both the total amount of opioids administered and in
the dose administered during the first 24 h, could be pri-
marily related to the factors mentioned above: develop-
mental pharmacokinetic, medications’ differences, and
the use of conversion tables. These variables could have
influenced the relationship between COMT polymorph-
ism and the opioids doses.
In light of these considerations, the secondary aim of
the present study (whether the impact of rs4680 poly-
morphism is age-dependent) is not completely pointed
out. Our results suggest that, independently from age,
rs4680 could actively influence the efficacy of pain ther-
apy also in children. Future studies, with large number
of paediatric patients, are needed to fully ascertain the
trend towards association shown also by our observa-
tional data.
Current guidelines encourage accurate monitoring of
pain in children and its treatment [2] in order to reduce
as much as possible, the psychological and behavioral ef-
fects of the pain sensation, whose impact is greater in
subjects during growth [44]. However, pain perception
and ability to report it is not homogeneous within the
paediatric population making it necessary to use differ-
ent pain evaluation scales, which for younger subjects
rely only on signs: this can be another factor concurring
to increase the inter-individual variation in the requested
opioid dose, particularly during the initial titration
phase. Furthermore, the inclusion of different pain rating
scales raises the problem of consistency between the
scales, although FLACC scores were reported to be
comparable to those generated using 0-to-10 number
rating scales [45], and pain severity ratings with the
Wong & Baker scale resulted highly correlated with
those of VAS [46].
The number of enrolled patients in the STOP Pain
study was relatively small. However, the uniform treat-
ment regimen, with 69% of patients receiving titration of
morphine by continuous i.v. infusion, reduces the effect
of this shortcoming. Future studies should prospect a
multi-center collaborative setting to address this point.
Moreover, regarding pharmacological treatment, we
could not establish whether any non-opioid analgesics
Fig. 2 Forest plot of the comparison of STOP Pain data with those included in the systematic review, relative to the 24-h opioid cumulative dose
(when reported as mean ± SD)
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used in our sample may have affected pain ratings and
side effects. This information would be very important,
since some agents may synergize with opioids and/or
have similar genetic influences on metabolism and/or
drug sensitivity.
Another limitation is represented by the mixed nature
of pain in cancer patients. In fact, paediatric cancer pain
can vary from acute, procedure-related pain to progres-
sive chronic and breakthrough pain, associated to dis-
ease progression and/or treatment. Moreover, due to the
relatively small sample size when considering the wide
variability of cancer diagnoses, it was difficult to state
whether the type and location of the primary cancer or
metastases influenced the pain measurements independ-
ent of genetic influences on opioid metabolism and re-
ceptor activity. Thus, whether cancer-associated pain
may represent an additional bias, it may only be deter-
mined through a large study including comparison of
patients with pain of different origins. Finally, an add-
itional obvious limitation is that the present results in
children can only be compared with those reported in
studies conducted on adults, simply due to the lack of
similar studies in paediatric subjects. On the other hand,
comparison of paediatric data with those obtained in
adults, collected in a systematic review, has shown dif-
ferences in the relevant parameters (24 h dose vs. total
dose) providing useful information for future studies in
children.
Conclusions
The results of this research show that paediatric cancer
patients with the GG genotype, compared with the
A-containing genotypes, received a higher mean dose of
morphine equivalents and needed a longer time to reach
the lowest possible pain intensity. These results suggest
that the presence of A allele in COMT rs4680 SNP
could represent an evaluable marker of opioid sensitivity
in paediatric cancer patients, as well as in adults. Al-
though further studies are needed to confirm these find-
ings, to date these evidences are still not sufficient to
support a previous expensive evaluation of COMT SNPs
before starting an opioid therapy in children suffering
for cancer pain.
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